Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 100.44K | 827.41K | 334.18K | 1.39M | 0.00 |
Gross Profit | 100.44K | 827.41K | 327.91K | 1.39M | -14.84K |
EBITDA | 360.57K | -2.10M | -8.19M | -24.31M | -14.87M |
Net Income | -2.62M | -3.78M | -9.24M | -25.12M | -14.33M |
Balance Sheet | |||||
Total Assets | 3.03M | 1.49M | 3.13M | 8.28M | 18.32M |
Cash, Cash Equivalents and Short-Term Investments | 1.23M | 94.49K | 2.47M | 6.66M | 16.12M |
Total Debt | 12.29M | 8.18M | 7.67M | 4.98M | 1.03M |
Total Liabilities | 16.43M | 12.42M | 10.53M | 11.55M | 5.56M |
Stockholders Equity | -13.40M | -10.92M | -7.40M | -3.27M | 12.75M |
Cash Flow | |||||
Free Cash Flow | 866.46K | -2.49M | -10.10M | -19.08M | -11.46M |
Operating Cash Flow | 868.82K | -2.46M | -10.10M | -19.08M | -11.45M |
Investing Cash Flow | -2.36K | -29.06K | -3.17K | 5.06M | -4.99M |
Financing Cash Flow | 193.68K | 122.05K | 5.91M | 9.56M | 17.02M |
Appili Therapeutics has re-launched LIKMEZ, the first FDA-approved liquid oral suspension of metronidazole, in the U.S., addressing a significant gap for patients who have difficulty swallowing tablets. The company is also progressing with its ATI-1701 vaccine candidate for tularemia, supported by U.S. Air Force funding, and ATI-1801 for cutaneous leishmaniasis, with positive Phase 3 data. These developments highlight Appili’s strategic focus on infectious disease solutions and potential market impact.
Appili Therapeutics announced the formal termination of its arrangement agreement with Aditxt Inc., effective May 30, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000 from Aditxt. Additionally, Appili has secured three-month extensions on loans from Long Zone Holdings Inc. and Bloom Burton & Co. Inc., with repayment due by August 31, 2025. This termination and financial adjustments may impact Appili’s operations and financial positioning, but the company continues to focus on its mission to combat infectious diseases.
Appili Therapeutics announced that Aditxt, Inc. has issued a notice to terminate their arrangement agreement effective May 31, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000, which may impact the company’s financials and strategic positioning in the biopharmaceutical industry.
Appili Therapeutics announced the publication of a manuscript in Frontiers in Bacteriology, highlighting the potential of their biodefense vaccine, ATI-1701, in preventing tularemia outbreaks. The review consolidates recent findings on immune responses to Francisella tularensis, the pathogen causing tularemia, and suggests pathways for effective vaccine development. ATI-1701 is positioned as a potentially valuable vaccine due to the lack of approved vaccines for tularemia in major markets, emphasizing its importance as a biodefense priority globally.
Appili Therapeutics has announced the granting of new patents by the United States and Mexican patent offices for its oral formulation of metronidazole, LIKMEZ. These patents, which expire in 2039, enhance the protection of LIKMEZ by covering its unique taste-masked composition and therapeutic applications. This development is significant for Appili as it strengthens the company’s market position and supports the commercialization efforts of its partner, Saptalis Pharmaceuticals. The listing of the U.S. patent in the FDA’s Orange Book further solidifies the product’s market presence, with Saptalis planning a re-launch under its own label.